Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01043263 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of EN3324 (Axomadol) in Subjects With Chronic Low Back Pain
A Phase 2 study, sponsored by Grünenthal.
- Completed
- Registry status
- Phase 2
- Development phase
- 236
- Enrollment target
NCT01043263 is a Phase 2 study that has completed, run by Grünenthal. The registered enrollment target is 236 participants.
The verdict
NCT01043263, a Phase 2 study, has completed, sponsored by Grünenthal.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 236 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy and safety of EN3324 (axomadol) in subjects with moderate to severe chronic low back pain
Interventions
- DRUG Placebo
- DRUG EN3324 (axomadol)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 236 participants |
| Start Date | 2009-12 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01043263
The ClinicalTrials.gov registry entry for NCT01043263 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 236 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Grünenthal, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01043263 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01043263 about?
NCT01043263 is a clinical study titled "Efficacy and Safety of EN3324 (Axomadol) in Subjects With Chronic Low Back Pain". The purpose of this study is to determine the efficacy and safety of EN3324 (axomadol) in subjects with moderate to severe chronic low back pain
What is the current status of trial NCT01043263?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 236 participants. The study started on 2009-12. Estimated completion is 2011-06.
What interventions are being tested in trial NCT01043263?
The interventions under investigation include: Placebo (DRUG), EN3324 (axomadol) (DRUG).
Who is sponsoring clinical trial NCT01043263?
This trial is sponsored by Grünenthal, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.